ABTI (Alterola Biotech) Total Liabilities: $3.62 Mil (As of Sep. 2024)


What is Alterola Biotech Total Liabilities?

Alterola Biotech ABTI Total Liabilities is $3.62 Mil as of Sep. 2024.

Alterola Biotech's Total Liabilities for the quarter that ended in Sep. 2024 was $3.62 Mil.

Alterola Biotech's quarterly Total Liabilities increased from Mar. 2024 ($1.33 Mil) to Jun. 2024 ($1.51 Mil) and increased from Jun. 2024 ($1.51 Mil) to Sep. 2024 ($3.62 Mil).

Alterola Biotech's annual Total Liabilities increased from Mar. 2022 ($1.20 Mil) to Mar. 2023 ($2.29 Mil) but then declined from Mar. 2023 ($2.29 Mil) to Mar. 2024 ($1.33 Mil).

Alterola Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Alterola Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterola Biotech Total Liabilities Chart

Alterola Biotech Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Mar22 Mar23 Mar24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.34 1.20 2.29 1.33

Alterola Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.52 1.36 1.33 1.51 3.62

Alterola Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alterola Biotech's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.333+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.33

Total Liabilities=Total Assets (A: Mar. 2024 )-Total Equity (A: Mar. 2024 )
=0.004--1.33
=1.33

Alterola Biotech's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.615+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.62

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=1.364--2.251
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $3.62 Mil mean?
Alterola Biotech (ABTI) has a Total Liabilities of $3.62 Mil as of Sep. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alterola Biotech and its competitors.
Is Alterola Biotech's Total Liabilities too high?
Alterola Biotech's current Total Liabilities is $3.62 Mil.
How does Alterola Biotech's Total Liabilities compare to SKYI and GCAN?
Alterola Biotech's Total Liabilities of $3.62 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alterola Biotech and its competitors. Alterola Biotech's current Total Liabilities is $3.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterola Biotech stock overvalued right now?
Alterola Biotech (ABTI) has a current Total Liabilities of $3.62 Mil. The current Total Liabilities is $3.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Alterola Biotech (ABTI), the current Total Liabilities is $3.62 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterola Biotech Business Description

Address 47 Hamilton Square, Birkenhead, Merseyside, GBR, CH41 5AR
Alterola Biotech Inc is a pharmaceutical company working with cannabinoid and cannabinoid-like molecules. The company operates in three focus areas: Development of regulated pharmaceuticals (human and animal health) and regulated food products; Production of low cost of goods Active Pharmaceutical Ingredient (API) and food-grade ingredients; and Formulation, and drug delivery, providing improved bioavailability, solubility and stability.